Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• T cells engineered with chimeric antigen receptors are FDA-approved, but native T-cell receptor-based therapies also show promise.
• Tumor antigens are less immunogenic than viral antigens, and tumors employ evasion strategies like antigen loss and suppressive cells.
• Infusion of antigen-specific T cells is generally well-tolerated, with responses linked to immune activity and epitope spreading.

Purpose of the Study:

• To discuss the use of T cells recognizing tumor antigens via their native T-cell receptors.
• To explore strategies for improving the efficacy of these T-cell therapies against cancer.

Main Methods:

• Reviewing current research on ex vivo culture conditions to enhance T-cell persistence and activity.
• Evaluating combinations with immune checkpoint inhibitors and epigenetic modifiers.
• Discussing engineering T cells to target multiple antigens and resist inhibitory factors.

Main Results:

• Antigen-specific T-cell infusions are well-tolerated and associated with clinical responses.
• Tumor evasion mechanisms pose significant obstacles to sustained therapeutic effects.
• Ongoing research aims to optimize T-cell function and overcome resistance.

Conclusions:

• T cells utilizing native T-cell receptors offer a viable approach for cancer immunotherapy.
• Strategies to enhance T-cell persistence, overcome tumor evasion, and improve activity are crucial for clinical success.
• Further research into optimizing T-cell manufacturing and combination therapies is essential.